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Introduction 
 Glaucoma is a leading cause of blindness among older adult Americans.  Despite 
the practice of evidence-based treatment for glaucoma there exists a high rate of failure to 
prevent loss of vision, even in patients receiving current glaucoma care.  Non-compliance 
has received the greatest attention in the literature with respect to measurable factors 
associated with loss of vision in glaucoma. However, in order to improve glaucoma care 
and minimize preventable vision loss, further investigation is needed into the range of 
additional and underlying factors that may not be quantifiable in nature. 
 This study used qualitative methods using procedures of focus groups to obtain 
original source data from glaucoma patients, their support systems (family members and 
friends), and glaucoma eye-care as to why vision loss occurs in glaucoma patients and 
what areas may be a point for intervention.  The purpose of this study was to characterize 
potentially new content areas and expand upon those previously suggested for 
intervention or additional investigation with respect to factors associated with vision loss 
identified by these focus groups.   
 
Burden of  Glaucoma 
 Vision loss among the elderly population in the United States is a significant 
problem facing public health. The population of elderly Americans is increasing rapidly 
and is estimated to approach 70 million within the next twenty-five years.  
Approximately one-third of the elderly population is afflicted by an eye-disease resulting 
in visual impairment, and over the next 30 years the number of Americans with visual 
impairments could double.
1
 Loss of vision is associated with decreased social function 
 2 
and ability to perform daily living skills,
2  
loss of independence and mobility,
3 4
 and 
increased depression.
5
 In a recent survey, elderly Americans reported loss of vision 
among their greatest fears.  Furthermore, based on data from a report titled, "Economic 
Costs of Visual Disorders and Disabilities: United States, 1981,‖ in 2003 the National 
Eye Institute (NEI) estimated current economic burden associated with ocular morbidity 
in the U.S. at $67.6 billion in total costs including both direct medical costs and indirect 
costs such as loss of wages, disability, and institutionalization.
6
 Most recently, Prevent 
Blindness America (2006) estimated the annual economic impact of adult visual 
impairment in the U.S. to be $51.4 billion in financial burden to the economy as well as 
medical care costs and health utility loss for the individual patient, caregivers, and 
healthcare payers.  
 Among patients with diagnosed visual disorders, between the ages of 40-64, 
direct annual medical costs for outpatient, inpatient, and prescription drug services 
associated with glaucoma are exceeded only by refractive error.
1
 When the age group is 
expanded to additionally include patients greater than 65 years of age, the total direct 
medical costs associated with glaucoma is ranked third among visual disorders exceeded 
by refractive error and cataracts, but remains associated with the greatest number of 
prescribed medications for all visual disorders among both age groups (40-64, and >65).   
 Glaucoma is a leading cause of vision loss among elderly Americans, and is the 
most common cause of blindness among older black Americans. The most recent 
estimate of prevalence for adults 40 years of age or greater with open-angle glaucoma in 
the U.S. was 1.86 percent.
7  
 In 2002 the NEI reported that 2.2 million Americans have 
been diagnosed with glaucoma, and another estimated two million are affected but do not 
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know they have it.  Furthermore, among those who have been left legally blind due to 
glaucoma, approximately 75 percent are over 65 years of age. As the elderly population 
continues to grow, this number will increase.    
 
Glaucoma Treatment and Vision Loss 
Glaucoma is a chronic and progressive disease that results in increased intraocular 
pressure and ultimately optic nerve damage and visual field loss.  Frequently, patients 
with glaucoma are initially asymptomatic and only begin to experience symptoms, such 
as significant blurred vision or diminished visual field, late in the progression of the 
disease at which time functional loss of vision is not recoverable. Retrospective analysis 
has identified several quantifiable risk factors associated with progression of visual field 
loss to blindness, including: poor compliance, increased age, greater initial visual field 
loss upon presentation, and higher variability in intraocular pressure (IOP) during 
treatment.
8 9
 
At the present time, reduction and control of IOP is the only clinically modifiable 
factor demonstrated to slow progression of glaucomatous optic neuropathy and associated 
loss of vision in glaucoma.
10-12
 Data exists for the relative effectiveness of specific 
treatments and procedures to lower IOP across the spectrum of disease severity from 
glaucoma suspects and patients with ocular hypertension, to patients diagnosed with 
early, moderate or advanced glaucoma. Historically, treatment and management of 
glaucoma has focused on sustained IOP values of less than 21mmHG or a target 
reduction in IOP of 30 percent or more, which is associated with lower probability of 
optic disk pathology.
10-15 
Studies have additionally demonstrated an association between 
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diurnal fluctuations in IOP and progressive visual loss in glaucoma, specifically that 
minimizing variance in IOP fluctuation improves outcome in glaucoma.
16-19
 
Topical pharmacotherapy is highly efficacious and remains first-line treatment for 
glaucoma.  However, we also know that clinical effectiveness of glaucoma treatment 
real-world practice outside of controlled clinical studies deviates from these ideals.  
Specifically, several retrospective cohort studies of glaucoma patients have demonstrated 
that despite our clinicians’ best efforts to provide efficacious medical and surgical 
therapy, some patients progress to blindness.
20-22   
For example, Hattenhauer et al. (1998) 
calculated that in a population of newly diagnosed glaucoma patients the probability of 
progression to legal blindness resulting from open-angle glaucoma (OAG) in at least one 
eye to be 27% at 20 years even with medical treatment, surgical intervention, or both.
23  
Similarly, Chang et al. (2005) also estimated that despite glaucoma treatment the 
probability of developing blindness in at least one eye due to glaucoma was 
approximately 29% at 16 years.
24
 
Studies using blindness as a main outcome measure generally do not include 
assessment of progression of functional vision loss as an additional outcome measure. 
Therefore, the proportion of patients affected by progressive and continued vision loss 
resulting from OAG is likely greatly underestimated by these figures. For example, in a 
study assessing progression of visual loss in a population of patients with diagnosed or 
suspected glaucoma, Wilson (2002) demonstrated that 16% based on Advanced 
Glaucoma Intervention Study (AGIS) criteria and 35% based on Collaborative Initial 
Glaucoma Treatment Study (CIGTS) criteria of those with untreated glaucoma would 
advance to end-stage glaucoma in at least one eye over 10 years.  However, over this 
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same interval continued progression of visual field loss by AGIS criteria occurred in 54% 
of total eyes included in the study.
25 
Additionally, independent studies have reported 
visual field loss rates of approximately 2% up to 5% per year in glaucoma patients even 
when receiving specialist care.
21 22 
However, survey data suggests patients may hold a 
different perspective of this risk over time. For example, at the time of diagnosis, 34% of 
glaucoma patients enrolled in the CIGTS reported at least moderate fear of blindness; 
however, over a five year period of time, this decreased to only 11% despite evidence 
demonstrating sustained risk of progressive visual field loss.
26
 
 Collectively these studies demonstrate a critical need to understand why patients 
may not receive or may not optimize use of efficacious glaucoma care. The specific 
factors involved in providing optimal individualized care that result in best patient-
centered treatment outcome are likely complex, interrelated, and poorly understood. To 
date, emphasis has been placed on patient non-compliance with recommended care as a 
postulated major contributing cause of loss of vision in glaucoma, with estimates of 
patient non-compliance ranging anywhere between 5 and 80 percent.
13 27-29
 Although 
non-compliance is clearly a factor associated with loss of vision in glaucoma, it likely 
serves as an intermediary but not ―root cause‖ of loss of vision and further fails to 
provide descriptive and qualitative information necessary to identify underlying factors.    
 Contributing factors may not be limited to patient-specific behavior, and may 
extend into the capacity of family members, eye-care providers and even the health care 
system.  For example, content areas warranting specific interest may include preferred 
patient-physician relationship styles (e.g. provider honesty and understanding), 
preferences and expectations in treatment (e.g. involvement in care), and level of 
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knowledge or understanding of disease (e.g. learning style for receiving and assimilating 
information). 
30-33
 
 
Purpose of the Study 
The purpose of this study is to qualitatively capture a broader as well as deeper 
insight into factors and barriers identified in vision loss in glaucoma patients despite 
receiving recommended and appropriate clinical care and also to identify additional areas 
for possible investigation and intervention to optimize glaucoma treatment and reduce 
vision loss. Accordingly, development of a more comprehensive understanding may be 
best accomplished through direct solicitation of information from multiple stakeholder 
perspectives such as: glaucoma patients; patients’ family or friends that serve as primary 
support system or caregiver; and ophthalmologists or optometrists providing glaucoma 
care.  
In order to approach this, we sought to use focus groups to obtain this 
information.  Focus group design is an established and useful tool for collecting and 
evaluating this type of qualitative information. Specifically, this format promotes detailed 
description of individual and group perspective as expressed directly from the subjects 
themselves.
34
 In the present study, use of focus groups facilitated identification of unique 
experiences and insights held by glaucoma patients, their family members and friends, 
and eye-care providers involved with glaucoma patient care.  The content area analysis 
provided information regarding concurrence as well as discordance between patient, 
family member, and provider deeper perspective into specific causes of loss of vision in 
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glaucoma, and provided focused areas of potential intervention to minimize its 
occurrence.  
 
Methods 
Study Participants 
Recruitment for focus group participants occurred at three collaborating teaching 
university ophthalmology centers: The University of California in Los Angeles; Duke 
University in Durham, NC; and The Mayo Clinic in Rochester, Minnesota.  This study 
was approved by the Duke University Institutional Review Board (protocol #364983ER).  
Efforts were made during recruitment to include participants that were representative of 
both genders, a range of ethnicities, and diverse socioeconomic and educational 
backgrounds when applicable.   For this study, three specific types of focus groups 
included: glaucoma patients with varying degrees of vision loss, family members and 
friends of glaucoma patients that were involved in their lives, and eye-care providers that 
treated glaucoma patients, including optometrists, general ophthalmologists, and 
glaucoma specialists.   
 
Participant Inclusion Criteria 
General criteria for participation in any focus group type included: greater than 18 
years of age, proficiency with the English language, and ability to provide informed 
consent.  Specific requirements for participation in the glaucoma patient focus group 
were prior diagnosis of glaucoma with varying severity of loss of vision, no confounding 
ophthalmologic conditions causing loss of vision (LOV) (e.g. Age-related Macular 
Degeneration, Proliferative Diabetic Retinopathy), and under current treatment for 
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glaucoma.  In order to maximize patient comfort with respect to participation, patient 
focus groups were organized to by two criteria: whether significant visual loss had 
occurred for the glaucoma patient, and their level of education, and groups were 
composed of members with similar visual status, and additionally with similar 
educational background when possible. In addition, eye-care providers were not present 
at any of the patient focus groups sessions in order to encourage participants to feel 
comfortable and be forthright in discussion topic responses. 
Additional criteria for participation in the family member and friend focus group 
were: (1) lives with a person diagnosed with glaucoma and provides them assistance; or 
(2) functions as the primary family member responsible for the person (if not living in 
same household); or (3) functions as the primary and direct support structure for the 
person (if not living in same household). Eye-care providers were not present at any of 
the family member and friend focus groups sessions. 
Participation in the eye-care provider focus group required current board-
certification and state licensure in their given occupation, minimum of 5 years since 
completion of training, and provision of glaucoma care accounting for greater than 20% 
of their practice. 
 
Focus Group Procedures 
 A standardized semi-structured script, specific to each focus group type, based in 
part on a previous visual function study funded by the National Eye Institute (1998) and 
prior standardized protocols,
19  
was employed at each site during every focus group 
session to guide discussion. Prior to focus group sessions, nine pilot interviews were 
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performed across the participating sites (three per site) to ensure that topics were 
appropriate and clear, and were additionally used to revise the focus group script.  The 
resulting focus group topic questions were derived and reviewed by all of the study 
investigators involved in creating the script.  During each focus group session, a trained 
facilitator or moderator was present whose role was to initiate and help direct 
conversation and participation through a specific scripted series of questions.  These 
facilitators received standardized protocol training by one of the study principal 
investigators and were not directly involved in delivery of glaucoma patient care. 
The general topic for the patient, the family member, and the eye-care provider 
focus groups was related to why patients with glaucoma might lose vision.  To relieve 
formality, focus group sessions generally began with introductions and sharing of 
personal experiences with respect to glaucoma.  During discussion, general standardized 
probes were presented as open-ended questions with respect to loss of vision in glaucoma 
patients and potential ways to improve patient outcome. Additional specific probe 
question topics were guided by possible factors identified in previous studies.  These 
topics included: general knowledge of glaucoma and treatment, specific perceived causes 
of glaucoma treatment failure and loss of vision, expectations of care and treatment, and 
specific actions that could minimize loss of vision in glaucoma. Throughout all sessions, 
probe questions were presented to the focus group as a whole, and participants could 
chose whether or not to provide a response.  Respondents were encouraged to be wide-
ranging and elaborative in their personal experiences, comments, and suggestions.  All 
focus group sessions were either audiotaped or videotaped, and were then directly 
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transcribed verbatim. Only the first names of participants were used as personal 
identifiers during focus group sessions to prevent potential linkage to patient charts.    
 
Focus Group Content Analysis Procedures 
Transcripts from focus group sessions were initially reviewed to identify any and 
all possible responses to the given probe questions and were then further examined for 
common categorical themes of comments. Subsequently, all remaining potential 
participant identifiers were removed when all comment taken directly from the transcripts 
were first coded and then organized into mutually exclusive response categories based 
upon the main theme of response with respect to the question of interest.  Specifically, 
content analysis was performed on the coded data to determine the frequencies of 
response categories within a specific focus group type and for comparison between 
different focus group types. Samples of transcripts from patient, family member and 
friend, and eye-care provider focus groups, were independently reviewed by various 
research members to evaluate reviewer correspondence.  For the purposes of self-
validation, kappa statistics were calculated at greater than 0.70 for independent reviewer 
agreement on a sample of transcribed data; however, due to the qualitative nature of this 
study and use of nominal categories to organize data, this was not necessary or especially 
informative for the data analysis and reporting.
35
 
 
Results 
Focus Group Participant Characteristics 
A total of 26 glaucoma-specific focus groups including patient groups, family 
member groups, and eye-care provider groups were conducted at three collaborating 
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teaching university ophthalmology centers.  The geographic locations of these centers 
included: Los Angeles, California; Durham, North Carolina; and Rochester, Minnesota.  
Characteristics of the focus group types are described in Table 1.   
 
Perceived Causes of LOV 
Patient Focus Groups 
Within patient focus groups, 61 comments with respect to perceived causes of 
loss of vision (LOV) in glaucoma were categorized into nine distinct response categories 
(Table 2).  The categories for causes of LOV reported by patient focus groups from most 
to least common included:  patient non-compliance; being ―unsure‖/uncertain of the 
causes; cost of medications and related care; being unaware of consequences due to 
asymptomatic nature of glaucoma; lack of continuity of care or change of eye-care 
provider; missed or delayed diagnosis; lack of education; uncontrolled IOP; and ―optic 
neuropathy‖.  Comments emphasizing patient non-compliance with medication regimen 
and routine recommended care (e.g. complexity of medication routine, difficulty with 
application of medications, side effect profiles, and keeping up with appointments) 
constituted more than a third of responses (36%). Within the set of reported factors 
related to LOV, those that demonstrated an understanding of the disease process involved 
in glaucoma were least reported, for example, uncontrolled IOP (3%) or ―optic 
neuropathy‖ (3%).  However, the patient group provided a unique response category 
related to causes of LOV in glaucoma, namely, that change of eye-care providers was an 
important factor (10%).    
Family Member and Friend Focus Groups 
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Compared to patient and eye-care provider groups, the family member and friend 
focus groups provided the fewest number of total comments (16) as well as distinct 
response categories (4) regarding perceived causes of LOV in glaucoma (Table 2).  The 
most frequently reported response categories were:  being ―unsure‖/uncertain of the 
causes of LOV (50%), followed by the cost of glaucoma medication and associated 
glaucoma care (25%).  Comments by family member and friend focus groups that were 
categorized into the ―unsure‖ response category included mainly descriptions of personal 
lack of knowledge with respect to causes of LOV in glaucoma.  Comments also included 
those suggesting the patient him/herself did not know the causes of glaucoma-related 
LOV or that the patient with whom they were directly involved had information about 
their glaucoma but ―kept information‖ from the family members and friends. Except for 
those personally diagnosed with glaucoma, family members and friends confirmed 
having little general familiarity with respect to glaucoma, treatment, and its effects on 
vision.   
Eye-Care Provider Focus Groups 
The eye-care provider focus groups produced the greatest number of total 
comments (77) and distinct response categories (11) with respect to perceived causes of 
LOV in glaucoma (Table 2). The causes of LOV reported by eye-care providers in 
decreasing frequency included: patient non-compliance; delayed or missed diagnosis; 
cost of related care and medications; patients being ―unaware‖ due to asymptomatic 
nature of glaucoma; lack of patient education; provider avoidance in relaying ―bad news‖ 
to the patient and family; lack of appropriate referral either from primary care provider to 
ophthalmologist, or from general ophthalmologist to glaucoma specialist; absence of 
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available ―cure‖; patient has other more serious medical problems; IOP is not a 
meaningful measure of patient outcome; and being personally ―unsure‖ or uncertain.  The 
eye-care providers reported five unique response categories concerning perceived causes 
of LOV not included in the patient or family member focus group response sets, most of 
which centered on clinical issues at the provider or health system level: provider 
avoidance, lack of appropriate glaucoma referrals, absence of available ―cure‖, patient 
has more serious medical issues, IOP is a poor measure of patient outcome. 
 
Recommended Potential Areas of Intervention 
Patient Focus Groups 
Patient focus groups mentioned 24 total recommendations regarding areas for 
potential intervention to reduce LOV in glaucoma that were organized into four distinct 
response categories (Table 3). These recommendations included from most to least 
common:  improving patient education about glaucoma and medication compliance; 
closer patient follow-up by providers; provider honesty with patient and relationship of 
trust; and provider sensitivity and interest in the individual patient. One-half of all 
comments with respect to suggested areas of intervention focused on improving of patient 
education. It was explicitly recommended that eye-care providers present both general 
information about glaucoma care and the consequences and effects of non-compliance 
with medications and recommended care.  Additionally, patients emphasized the 
importance of receiving information concerning diagnosis and treatment at a level 
comprehensible to them. For example, most patients described being presented with 
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information that was either too complex (e.g. ―too much‖ or ―too detailed‖) or inadequate 
(―not enough‖ to understand).  
Family Member and Friend Focus Groups 
Family members suggested the fewest number of total comments (14) and 
response categories (3) concerning potential areas of intervention aimed to reduce LOV 
in glaucoma (Table 3).  Potential actions suggested by family members to reduce LOV in 
glaucoma from most common to least included: increasing family member education and 
involvement; improving patient education about glaucoma and treatment; improving 
provider honesty and trust with the patient and family.  Although the recommendation to 
improve patient education and provider honesty was the most common recommendation 
provided by family member groups, increasing or improving family member education 
and involvement was not a recommendation reciprocated by the patient groups.  
Eye-Care Provider Focus Groups 
Eye-care providers suggested the greatest total number recommendations (40) and 
response categories (13) regarding potential areas of intervention to reduce of loss of 
vision in glaucoma patients.  Most to least commonly suggested actions that overlap with 
patient or family member recommendations included:  closer patient follow-up by 
providers; improving patient education about glaucoma and medication compliance; 
provider sensitivity and interest in the individual patient; provider honesty with patient 
and building a relationship of trust; and greater family education and involvement.  
Although recommendations by eye-care providers demonstrated concurrence with those 
supplied by patient and family members, eight unique response categories for areas of 
potential intervention are shown in Table 3.  These areas for intervention focused on 
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provider care practices and education, as well as changes within current health care 
delivery practices.  Specific comments and recommendations related to provider practices 
included: tighter follow-up with their glaucoma patients including periodic ―medication 
checks‖ and ―appointment reminders‖; and improving physician-patient relationship 
through attention to the individual needs and preferences of patients. Specific 
recommendations related to health care system practices included: increasing rates of 
referrals for specialized glaucoma care; ―standardizing glaucoma care‖ to reduce 
provider-reported variation in care across eye-care professionals; and increasing public 
awareness of glaucoma through media campaigns.  
 
 
Discussion 
 
This study revealed some interesting general patterns in distribution of response 
categories across focus group types.   Not surprisingly, regarding perceived causes for 
LOV the greatest number of total responses and distinct response categories were offered 
by eye-care provider groups, followed by patient focus groups, while the fewest were 
offered by family member focus groups. As demonstrated in Figure 1, patient focus 
groups uniquely reported frequent change in eye-care providers as a perceived and 
preventable cause of LOV in glaucoma, eye-care provider focus groups offered several 
unique response categories that accentuated eye-care provider and healthcare-centered 
topics, and family and friend focus groups did not offer any unique response categories.  
Overall, emphasis was placed on the following preventable causes of LOV in glaucoma: 
cost of glaucoma-related care, patient non-compliance, and being ―unsure‖ of or unable 
to identify any causes.   
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With respect to recommendations for potential areas of intervention, the greatest 
number of total responses as well as distinct response categories were provided by the 
eye-care provider groups compared to the fewest responses provided by the family 
member and friend groups.  Again, the eye-care providers also contributed the greatest 
number of unique recommended response categories, mainly focusing on issues related to 
the delivery and allocation of healthcare services (Figure 2).   All three types of focus 
groups emphasized the following major areas of potential intervention to minimize LOV 
in glaucoma: patient education and involvement in glaucoma care, and provider 
interpersonal and communication skills.  
 
Cost of Care 
Cost of glaucoma-related care was among the top three perceived causes of LOV 
in glaucoma cited by patients, family member or friends, and eye-care providers. 
Independent reporting across focus group types identifying cost as a major factor 
indicates this is a widely recognized problem. In 2007 Prevent Blindness America 
reported for patients 40-64 years of age with diagnosed visual disorders, glaucoma-
related direct annual medical costs for outpatient, inpatient, and prescription drug 
services were exceeded only by refractive error, and glaucoma was also associated with 
the greatest number of prescribed medications for all visual disorders.
1
 Survey data 
clearly demonstrates that older patients with chronic illnesses requiring prescription 
medications admit to intentionally underusing prescription medications in order to reduce 
the financial burden.
36 37
 
 17 
Cost of glaucoma-related care may be of special concern for the population of 
patients most affected by glaucoma, namely the elderly that frequently rely on Medicare 
coverage for health care services and medication. Continued efforts should be placed on 
reducing medication costs; and developing appropriate and cost-effective screening 
methods to improve early detection of glaucoma, thus avoiding the formidable cost of 
care and associated burden of advanced glaucoma.  Importantly, eye-care providers 
should initiate open discussion with patients regarding their financial situation and ability 
to pay for their medications to accomplish several goals: to identify those that require and 
may qualify for assistance programs, to minimize potential cost-associated issues of non-
compliance, to demonstrate personal interest and concern for the patient. 
Non-Compliance 
Patient non-compliance with medical treatment was the most frequently reported 
perceived preventable cause of vision loss in glaucoma reported by both the patient and 
eye-care provider groups, 26% and 31%, respectively.  Based upon large randomized 
controlled trials, use of topical hypotensives for medical management of glaucoma is 
considered first-line therapy, and not surprisingly, it is common for patients to require 
multiple medications used in complex schedules of administration.
10 13 38 
Perception of 
non-compliance contributing to LOV by patient and eye-care provider groups is 
consistent with previous research that reveals estimated alarming rates of non-compliance 
as high as 80% in glaucoma patients.
27-29
 Currently, the threshold for compliance required 
to achieve clinical effectiveness in reducing progression of visual field loss remains 
unquantifiable, thus the ultimate clinical consequence is unknown,
39 
demonstrating the 
need for  further insight into non-compliance. 
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The present study format was useful in describing specific challenges that 
underlie patient non-compliance, as reported directly from glaucoma patients.  The five 
most commonly identified specific barriers to compliance included: inconvenience or 
complexity of medication routine, difficulty in instillation of medication to the eye, 
physical discomfort or side effects of medication, frequent changes to medications, and 
difficulty in maintaining appointments. Upon further explanation, patients expressed 
great concern that increased reliance (―being dependent‖) on friends and family for 
assistance and transportation due to their declining vision was a specific barrier in ability 
to effectively self-administer medications, attend scheduled appointments, and even read 
appointment slips. Despite increased dependence on others, patients did not desire 
increased involvement or education for their family members or friends with respect to 
their glaucoma. This presents an opportunity for eye-care providers to investigate 
potential clinical management strategies that maximize patient autonomy. 
 
Uncertain of Causes  
Reporting that they were ―unsure‖ or lacked knowledge of the causes of 
preventable vision loss in glaucoma was the most frequent response provided by family 
members or friends (50%), and the second most common response provided by patients 
(13%). In contrast, eye-care providers rarely reported this response.  This is surprising 
considering that all of the patient participants were under current glaucoma care and all of 
the family member and friend participants were associated with patients under current 
care for glaucoma.  In addition, the minimum reported time since receiving a diagnosis of 
glaucoma was five years and the maximum was 43 years, thus uncertainty with respect to 
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causes of LOV was not a function of a ―new‖ glaucoma diagnosis. This finding is 
consistent with a recent cross-sectional study that demonstrated patients with established 
glaucoma have only slightly greater knowledge than newly diagnosed patients.
40
  
Furthermore, when asked to describe their personal level of knowledge of 
glaucoma, effects on vision, and treatment, patient participants self-reported degree of 
knowledge ranging from ―very little‖ to only ―some‖. No patients described their 
personal knowledge as greater than ―some.‖ These comments suggest a significant 
disconnect in dissemination of information that may be occurring at several potential 
levels including: general public knowledge, primary care providers, eye-care providers, 
glaucoma patients, and family members or friends of glaucoma patients. Glaucoma 
knowledge could be improved through various educational measures such as public 
awareness campaigns, direct patient and family member and friend education, and 
various educational materials. 
 
Education 
Issues regarding the lack of knowledge about glaucoma, its effects on vision, and 
treatment, as well as non-compliance may be approached through mechanisms of patient 
education.  Patient education was the most commonly recommended potential area of 
intervention by patient groups (50%) and the second most commonly recommendation by 
family member or friend groups (29%) and by eye-care provider groups (13%).  
Patient comments specifically highlighted the need to improve patient education 
and knowledge with respect to glaucoma as a chronic disease, compliance with treatment, 
and consequences of inadequate treatment on vision.  Many patients described personal 
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experience with being presented information that was inappropriate for their individual 
comprehension level or learning style (―too much‖ or that they ―didn’t understand‖), and 
factors such as comprehension and literacy have been recognized correlates of patient 
compliance and outcome.
42 43
 Of additional interest was the great variance in the 
―amount‖ and the ―detailedness‖ of information desired by patients with respect to their 
disease and treatment. Eye-care providers echoed these specific recommendations and 
further suggested that information about glaucoma, vision, and treatment, should be 
presented to patients in a meaningful way, for example, in terms of functional visual 
outcome rather than perimetry tests or relative IOP values. This is consistent with survey 
data from The Collaborative Initial Glaucoma Treatment Study that showed anxiety and 
fear of blindness in newly diagnosed glaucoma patients was highly correlated with self-
perceived visual function and not by clinical measures.
26 41
 
Collectively, this original-source data demonstrates a failing of our healthcare 
system to deliver information that is understandable and appropriate in format for this 
population of patients.  Further, it calls to question whether the individual provider or 
health system is overestimating the ―medical literacy‖ (ability to understand medical 
information and instructions) of these elderly patients.  Glaucoma patient and caregiver 
education could be improved through use of patient health educators that offer 
individualized information as seen in management of diabetes, simplification of 
educational materials, and diversification of accessible educational resources. 
Patient responses as well as eye-care provider responses also suggested 
educational interventions for physicians, such as training in continuity of care, and 
appropriate processes for referrals to specialists.  Specific recommendations included that 
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eye-care providers be up-to-date in current standards of care for diagnosis, treatment, and 
management of glaucoma, and general practitioners recognize when it is appropriate or 
necessary to refer patients to eye-care specialists without delay. Interestingly, as a 
proposed measure to reduce loss of vision in glaucoma, family members and eye-care 
providers also recommended increasing family education and involvement in patient 
care; however, no patients made such suggestions.  
 
Patient Involvement  
Although there was general agreement among the patient groups and eye-care 
provider groups that patients should receive closer follow-up for glaucoma care, there 
was discordance in the extent of desired patient involvement in their care, specifically 
with respect to decision-making in treatment choices. For example, consistent with the 
popular patient-integrated movement in health care that imposes active participation by 
the patient in decision-making, the eye-care providers in this study stressed the 
importance of patient involvement in decision-making processes.
44
 In contrast, patients 
expressed tremendous variance in the extent of desired level of involvement ranging from 
preference to self-determine treatment plan, to preference for being informed and actively 
making joint decisions with provider, to preference for provider to make treatment 
decisions on the patient’s behalf (―tell the patient what to do‖). This finding of great 
variance in individual patient preference for involvement in eye care is consistent with 
previous patient expectation studies regarding eye care.
32
  
Thus, patient preference for involvement in care deserves careful provider 
consideration especially when making decisions regarding long-term management of a 
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chronic disease such as glaucoma. Furthermore, providers must be cautious with respect 
to generalizing this desire to function as ―active participants‖ to glaucoma patient 
populations whom are frequently elderly with multiple comorbidities and variable 
cognition and literacy. Although the concept of patient-integrated medicine may 
approach the theoretical ideal, it may not coincide with the desires or cognitive or 
functional capabilities of the individual patient. 
 
Patient-Provider Relationship 
 Improving what can be described as the eye-care provider-patient relationship 
through provider honesty and provider sensitivity and personal interest in the patient was 
commonly suggested as an area of intervention to reduce preventable LOV in glaucoma. 
Establishing or increasing provider honesty with the patient and family was 
recommended by the patient groups (13%), family member and friend groups (29%), and 
eye-care provider groups (10%), and increasing provider interest in the patient and 
demonstrating sensitivity was suggested by the patient groups (13%) and the eye-care 
provider groups (13%).  In other studies, such factors have been characterized as provider 
interpersonal and communication skills and have been positively correlated with patient 
satisfaction with eye care,
31 32
 and likeliness to comply with treatment and be forthright 
with respect to reporting compliance.
33 45
   In addition, some subpopulations of non-white 
patients have even described lack of provider trust and honesty as an obstacle to receiving 
eye care.
30
 In this study, patients highlighted several specific areas of improvement 
within the patient-provider relationship, such as demonstrating patience, providing honest 
opinion or assessment, and spending adequate time addressing any patient concerns.  Of 
 23 
interest was that eye-care providers emphasized the great importance of provider honesty 
despite also acknowledging hesitancy in being completely forthright when forced to bear 
bad news to patients and families.   
 
Limitations of the Study 
 The patient population and their family members and caregivers consisted of 
those receiving care or associated with a patient receiving care at an academic eye-center, 
thus the generalizability of these findings to other patients and their family members and 
caregivers receiving care in a community-based or non-academic eye clinics is unknown.  
Although efforts were made to approximate equal gender representation within focus 
group types, compared to the general population there was greater female representation 
in the family member and friend groups, and less male representation in the eye-care 
provider focus groups.  However, the gender distributions in these two focus group types 
may actually translate to an approximation of the glaucoma family member and caregiver 
as well as eye-care provider populations, respectively. Gender bias could potentially 
cause over- or under-representation of the frequency of certain response categories; 
however, this would unlikely affect the range of elicited responses.  
 
Conclusion 
A challenge faced by ophthalmologists in treating patients with glaucoma is how 
to provide optimal, effective long-term care that minimizes preventable loss of vision 
commonly observed in clinical practice.  The objective of this study was to improve our 
qualitative understanding of contributory factors associated with loss of vision in 
 24 
glaucoma patients despite receiving treatment and to elicit potential areas of intervention 
to reduce this LOV.   Use of patient, family member and friend, and eye-care provider 
focus groups appeared to be valuable in emphasizing and expanding upon specific 
components that underlie previously recognized and emerging concepts for approaching 
the problem of preventable vision loss in patients receiving treatment for glaucoma.  Of 
special important for further investigation are ways to identify and apply patient 
preferences with respect to management and treatment of glaucoma, in specific areas 
such as: patient education style,
31 42 43 
patient involvement in care,
32 44
 and characteristics 
of provider-patient relationship.
30-33 45
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Table 1.  Focus Group Participant Characteristics 
 
 
 
Patient Participants 
       Total Groups    15 
Total Participants (n)   84 
Age Range (years)    43-90 
Time Since Diagnosis (years)  5-43 
Female (%)     49 
 
Family Member/Friend Participants 
 
Total Groups    6 
Total Participants (n)   31 
Female (%)     61 
 
Provider Participants 
 
Total Groups    5 
Total Participants (n)   35 
Time in Clinical Practice (years)  5-18 
Female (%)     20 
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Table 2. Perceived Causes of Loss of Vision 
 
                                         
         Group-Specific Responses n (%)  
Perceived Cause of LOV                     Family Member/           Eye-Care 
         Response Category          Patients          Friend      Provider 
       
Change of Providers     6 (10)    0 (0)          0 (0) 
Unsure      8 (13)    8 (50)          2 (2) 
Patient Non-compliance             22 (36)    0 (0)        24 (31) 
Cost of Obtaining Care    6 (10)    4 (25)        12 (16) 
Uncontrolled IOP     2 (3)    2 (13)          0 (0) 
Lack of Patient Education    5 (8)    0 (0)          6 (8) 
Asymptomatic     6 (10)    0 (0)           9 (12) 
Optic Neuropathy     2 (3)    0 (0)          0 (0) 
Missed/Delayed Diagnosis      5 (8)    2 (13)        12 (16) 
Provider Avoidance       0 (0)    0 (0)          5 (6)  
Lack of Referral     0 (0)       0 (0)                      3 (4) 
No Available Cure     0 (0)      0 (0)          2 (2) 
Other More Serious Conditions        0 (0)    0 (0)              2 (2) 
IOP Poor Measure     0 (0)     0 (0)                      2 (2)  
   Total Comments             61   16         77 
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Table 3. Suggested Potential Areas of Intervention to Reduce Loss of Vision 
 
 
                                             Group-Specific Responses n (%)  
 
   Potential Areas of Intervention      Family Member/      Eye-Care 
              Response Category            Patients          Friend      Provider 
       
Provider Honesty      3 (13)   4 (29)          4 (10) 
Tighter Follow-up      6 (25)   0 (0)          9 (23) 
Improve Patient Education    12 (50)   4 (29)          5 (13) 
Provider Sensitivity/Interest        3 (13)   0 (0)          5 (13) 
Family Education/Involvement     0 (0)        6 (42)          3 (8)            
Improve Provider Education       0 (0)   0 (0)          3 (8) 
Simplify Patient Literature       0 (0)               0 (0)                      2 (5) 
Improve Screening                    0 (0)     0 (0)          2 (5) 
Reduce Cost of Treatment        0 (0)   0 (0)          1 (3) 
Increase Referrals           0 (0)   0 (0)                     2 (5) 
Increase Public Awareness       0 (0)      0 (0)                     2 (5) 
Use of Standardized Care     0 (0)     0 (0)                     1 (3) 
Increased Appointment Time       0 (0)   0 (0)                     1 (3)
 
      Total Comments     24   14         40 
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Figure Legends 
 
 
Figure 1. Percentage of response comments with respect to perceived causes of LOV 
for patient, family member or friend, and eye-care providers. 
 
 
Figure 2. Percentage of response comments with respect to potential areas of 
intervention for patient, family member or friend, and eye-care providers. 
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